Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $221 from $212 and keeps a Buy rating on the shares.

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...

According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. | After several quarters of creeping up on Humira, ...

University of Chicago Medicine has received a $75 million donation from the AbbVie Foundation to help it build its massive new cancer hospital on the city’s South Side. The money will go toward ...

AbbVie cautions that these forward-looking statements ... but this one gives us a unique opportunity there to go head to head with vedolizumab, especially looking at endoscopic improvement.